𝔖 Bobbio Scriptorium
✦   LIBER   ✦

111 Final results of a multi-center phase 1b, randomized, placebo-controlled, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus

✍ Scribed by J.G. McHutchison; B.R. Bacon; S.C. Gordon; E. Lawitz; M. Shiffman; N.H. Afdhal; I.M. Jacobson; A. Muir; A. Vicari; S. Efler; M. Al-Adhami; M.L. Morris; H.L. Davis

Book ID
117374391
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
94 KB
Volume
44
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 1B, randomized, double-blind, dose
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
✍ John G. McHutchison; Bruce R. Bacon; Stuart C. Gordon; Eric Lawitz; Mitchell Shi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 397 KB πŸ‘ 1 views

CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. In this multicenter Phase 1b trial, 60 HCV-positive patients (50 genotype 1 HCV) were randomized and

Final results of a double-blind, placebo
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-Ξ³1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
✍ Paul J. Pockros; Lennox Jeffers; Nezam Afdhal; Zachary D. Goodman; David Nelson; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 383 KB πŸ‘ 2 views

## Interferon-β₯1b (IFN-β₯1b ) is a pleiotropic cytokine that displays antifibrotic, antiviral, and antiproliferative activity. A total of 502 patients with compensated liver disease and an Ishak fibrosis score of 4-6 were randomized in a double-blind, placebo-controlled study, and 488 of these pati